Johnson And Johnson Continues To Focus On Medical Innovation
Johnson And Johnson Continues To Focus On Medical Innovation
On Wednesday, Johnson & Johnson (NYSE:JNJ) reported its second quarter results that reflected a strong momentum of its medtech and innovative medicine divisions. Although one-time charges prevented topline growth from reaching the bottom line, Johnson and Johnson showed it continues to advance its drug pipeline for a new medical era, with significant clinical milestones being attained throughout the quarter.
周三,强生公司(纽交所:JNJ)公布了其第二季度财报,反映了其医疗技术和创新药物部门的强势势头。尽管一次性费用阻止了收入增长达到底线,但强生公司表明其继续推进新医疗时代的药物管线,整个季度取得了重大的临床里程碑。
Second Quarter Highlights
二季度亮点
For the June quarter, Johnson & Johnson reported topline growth of 4.3% YoY as sales grew to $22.45 billion, surpassing the FactSet consensus of $22.33 billion. Regionally, U.S. sales grew 7.8% YoY, bringing in $12.5 billion, while international sales remained flat at $9.8 billion.
就6月季度而言,强生公司报告了4.3%的年度收入增长,销售额增长至224.5亿美元,超过FactSet的预期223.3亿美元。在地区方面,美国的销售额同比增长了7.8%,达到了125亿美元,而国际销售额保持在98亿美元的水平。
Fueled by cancer drug Darzalex among other growth drivers, the innovative medicine segment recorded sales growth of 5.5%, bringing in revenue of $14.49 billion, also topping FactSet consensus of $14.12 billion.
在癌症药物Darzalex等增长驱动因素的推动下,强生公司的创新药物部门销售增长了5.5%,营业收入达到了144.9亿美元,也超过了FactSet的预期141.2亿美元。
The medtech division grew 2.2% to $7.96 billion, coming short of Fact Set's consensus of $8.17 billion
医疗技术部门增长了2.2%,达到了79.6亿美元,而Fact Set的预期为81.7亿美元。
As for Johnson & Johnson's best-selling drugs, psoriasis treatment Stelara recorded growth of 3.1% to $2.89 billion, surpassing FactSet consensus of $2.85 billion, while cancer treatment Darzalex recorded 18.4% growth with sales rising to to $2.878 billion, also slighly below the expected $2.885 billion.
至于强生公司最畅销的药物,治疗牛皮癣的Stelara的销售额增长了3.1%,达到了28.9亿美元,超过了FactSet的预期28.5亿美元,而治疗癌症的Darzalex的销售额录得18.4%的增长,销售额达到了28.78亿美元,略低于预期的28.85亿美元。
On the other hand, infectious disease drugs recorded a 13.9% drop with sales amounting to $965 million, while COVID-19 vaccine sales plummeted even more, falling 40% to $172 million.
另一方面,传染病药物的销售额下降了13.9%,销售额为9650万美元,而新冠疫苗的销售额更是暴跌了40%,降至1720万美元。
Due to one-time charges, net earnings fell almost 13% to $4.6 billion, with earnings per share dropping nearly 6% to $1.93. But adjusted for one-time items, EPS actually rose by 10.2% to $2.82.
由于一次性费用的影响,净收入几乎下降了13%,每股收益也下降了近6%,降至1.93美元。但在排除一次性项目后,每股收益实际上上升了10.2%,达到了2.82美元。
Slightly altered full year guidance
细微调整的全年指引
J&J raised the midpoint of its full-year guidance for operational sales from a $88.9 billion to $89.4 billion, fueled by the completion of the $13.1 billion acquisition of its newest medtech conquest, Shockwave Medical. But, due to the costs of this strategic acquisitions, it also lowered its full-year adjusted operational EPS guidance that are now expected in a range from $10 to $10.10.
强生公司将全年经营性销售指引中点从889亿美元上调至894亿美元,该数字受益于新收购的医疗科技公司Shockwave Medical的131亿美元收购。但由于这些战略收购的成本,因此强生公司也将其全年经调整后的经营性每股收益指引下调到10至10.10美元的区间。
The second quarter performance reflects focus on medical innovation.
第二季度业绩反映了对医疗创新的关注。
Throughout the quarter, the health care bellwether was busy with M&A. Besides completing the Shockwave deal, it scooped up bispecific antibodies biotech Proteologix for $850 million in cash. Johnson and Johnson also spent $1.25 billion to get Numab Therapeutics' experimental bispecific antibody that targets atopic dermatitis. In addition, J& J also had a few activities of the regulatory front during the quarter. Carvykti was greenlit by the Food and Drug Administration for second-line use in adults with relapsed refractory multiple myeloma, which J&J developed with Legend Biotech's. J&J also submitted an application to treat moderately to severely active Crohn's disease with Tremfya.
整个季度,这家医疗行业的风向标公司忙于进行并购。除了完成Shockwave交易外,它还以现金支付8.5亿美元收购了双特异性抗体生物技术公司Proteologix。强生公司还花费12.5亿美元收购了Numab Therapeutics的试验性双特异性抗体,该抗体针对特应性皮炎。此外,强生在本季度还在监管方面进行了一些活动。Carvykti获得了食品和药品监督管理局的批准,用于治疗成人复发难治性多发性骨髓瘤病患者的二线治疗,该药由传奇生物和强生公司共同开发。强生公司还提交了一份申请,用于治疗中度至严重活动性克罗恩病的Tremfya。
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
免责声明:本内容仅供参考,不构成任何投资建议。
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
本文来自非报酬的外部投稿人。它不代表Benzinga的报道,并且没有因为内容或准确性而被编辑。